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Abstract
Background The French Safety and Appropriateness of
Growth Hormone treatments in Europe (SAGhE) cohort
has raised concern of increased mortality risk during fol-
low-up into adulthood in certain patients who had received
growth hormone (GH) treatment during childhood. The
Hypopituitary Control and Complications Study monitored
mortality and morbidity of adult GH-deficient patients
including those with childhood-onset GH deficiency
(COGHD) who received GH treatment as children.
Purpose Evaluate risk of mortality, cancer, myocardial
infarction (MI) and stroke in a prospective observational study.
Methods COGHD patients [n = 1,204, including 389
diagnosed with idiopathic COGHD (ICOGHD)] had
received pediatric GH treatment. Standardized mortality
ratios (SMRs), and cancer standardized incidence ratios
(SIRs) in patients without a prior cancer were estimated
relative to reference populations. Crude incidence rates
were estimated for MI and stroke.
Results No increased mortality or cancer incidence was
observed, as compared with reference populations, during a
follow-up of 3.7 ± 3.3 years (mean ± SD). The overall
SMR for COGHD was 1.14 [95 % confidence interval (CI)
0.55–2.10], and for ICOGHD, 0.33 (0.01–1.84). The
overall cancer SIR for COGHD was 0.27 (0.01–1.50), and
for ICOGHD, 0.00 (0.00–2.45). No incident case of MI was
reported. The crude stroke incidence rate [181.3 per
100,000 person-years] in COGHD patients was consistent
with the rates reported in reference populations. No inci-
dent case of stroke was identified in ICOGHD patients who
are presumed to have no increased stroke risk factors.
Conclusions The results indicate no increased risk of
mortality or incidence of cancer, stroke, or MI in adult GH-
deficient patients who had previously received pediatric
GH treatment.
Keywords Growth hormone deficiency  Mortality 
Morbidity  GH treatment  HypoCCS  SAGhE
Introduction
The reported results of the study of Safety and Appropri-
ateness of Growth Hormone treatments in Europe (SAGhE)
raised concern regarding the long-term safety of recombi-
nant growth hormone (GH) therapy [1]. The study was a
retrospective evaluation of follow up on approximately
7,000 adults who were treated with recombinant GH during
childhood for idiopathic isolated GH deficiency, neurose-
cretory GH dysfunction, idiopathic short stature and born
short for gestational age. These patients, presumed to be at
no increased risk, were found to have an increased all-
cause mortality compared with the French reference pop-
ulation [standardized mortality ratio (SMR) = 1.33]. Fur-
thermore, the study reported increased mortality due to
diseases of the circulatory system (SMR = 3.07), sub-
arachnoid intracerebral hemorrhage (SMR = 6.66), and
bone tumor (SMR = 5.00). The mean period between start
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of childhood GH therapy and the time of census or death
was approximately 17 years. In contrast, the SAGhE
results from Sweden, Belgium, and the Netherlands did not
demonstrate any death from cancer or cerebrovascular
disease in approximately 2,500 patients studied [2]. Thus,
the safety of long-term GH treatment during childhood
remains inconclusive [3, 4].
The Hypopituitary Control and Complications Study
(HypoCCS), a global postmarketing surveillance study
conducted by Eli Lilly and Company, monitored clinical
outcomes of adult GH-deficient (GHD) patients [5]. Mul-
tiple safety-related HypoCCS analyses have been published
[6–10], and the HypoCCS GHD patients included subjects
with childhood-onset GH-deficiency (COGHD) who had
received GH treatment during childhood, similar to the
subjects in SAGhE. When the French SAGhE data were
published, the HypoCCS database included 10,190 subjects
who had been enrolled from the United States, Canada, and
14 European countries during the period 1995–2010. Of
these, 1,024 had a diagnosis of COGHD and a history of
prior pediatric GH treatment. These COGHD patients were
followed for an average of 3.7 years. Given the uncertainty
regarding long-term safety of GH treatment, we employed
the HypoCCS database to assess mortality and the inci-
dence rates for cancer, myocardial infarction (MI), and




Subjects enrolled in HypoCCS met the adult GH deficiency
indication for Humatrope [somatropin (rDNA origin) for
injection; Eli Lilly and Co, Indianapolis, IN, USA],
according to the prescribing regulation for each country.
Subjects had an established diagnosis of adult GH defi-
ciency, either alone or with multiple pituitary hormone
deficiencies, as determined by clinical history and bio-
chemical testing [5]. The diagnostic approach used and the
decision to administer GH was at the discretion of the
investigating site physician. It is unknown whether the
patients primed with sex steroids for the diagnostic tests.
Subjects were not eligible for enrollment if they had active
or unresolved contraindications to GH therapy, including
evidence or suspicion of active malignancy, evidence of
ongoing pituitary or other intracranial tumor activity,
pregnancy, or breastfeeding. HypoCCS was conducted in
accordance with the Declaration of Helsinki guidelines and
all applicable regulatory requirements in the respective
participating countries. Ethical review board approval and
written consent for data collection, electronic processing,
and publication were obtained in accordance with respec-
tive national laws.
For this analysis, we studied the 1,204 childhood-onset
GHD patients who were reported as having received
pediatric GH treatment and had available information on
age, gender, and at least one follow-up visit after study
entry (the COGHD group). Of these, 1,086 received GH
treatment as adults. Subjects with idiopathic COGHD (the
ICOGHD group) (n = 389), a subgroup of the COGHD
group presumed to be at no increased risk of mortality,
cancer, stroke, or MI, were also analyzed.
Mortality and incidence of cancer, stroke, and MI
Deaths and adverse events (AEs) were reported from the
HypoCCS case report forms (CRFs) for AEs. Lilly pharma-
covigilance databases that store spontaneously reported cases
were further searched to see if any cases were missed in the
HypoCCS CRFs. Any missed cases were added to the report.
Causes of death and AEs were coded in Medical Dictionary for
Regulatory Activities (MedDRA) terms (Version 14.0). Sub-
jects with stroke, MI, and cancer were ascertained in a com-
prehensive review process. For case ascertainment of stroke,
MedDRA preferred terms indicative of stroke were selected
from the central nervous system hemorrhages and cerebro-
vascular conditions Standardized MedDRA Query (SMQ),
and the patients with these terms were pre-selected. Of the pre-
selected patients, incident cases (new cases that occurred after
HypoCCS entry) were then identified by comprehensively
reviewing CRFs for patient demographics, pre-existing con-
ditions and comorbidities, historical diagnoses, physical
examinations, laboratory measures, somatropin dosing, con-
comitant medications, previous treatments, CRF comment
pages, and AE narratives [6, 7]. Cases of subarachnoid hem-
orrhage due to trauma were not accounted for as stroke cases
according to prior recommendation [11]. Similarly, for case
ascertainment of MI and cancer, the MedDRA preferred terms
indicative of the diagnoses of MI and cancers were selected
from the MI SMQ and the Malignancies SMQ, respectively.
After pre-selecting the patients with these terms, incident cases
of MI and cancer were ascertained by comprehensive review
similar to that conducted for stroke. Only incident AE cases
were included for analysis. Mean daily GH dose (micrograms
per day) received in HypoCCS was estimated from each fol-
low-up visit, excluding the dosing reported during the first
6 months of treatment.
Statistical analysis
For baseline demographics and clinical data, number
(N) and percentage (%) were summarized for categorical
variables (e.g., gender); mean and SD were summarized for
continuous variables (e.g., age).
478 Pituitary (2014) 17:477–485
123
The crude (unadjusted) incidence rate for each AE of
interest or the crude (unadjusted) mortality rate was cal-
culated by dividing the number of new cases observed
during the study period by the total person-years at risk
among patients with no history of the respective AE at
HypoCCS entry. For new cases, person-years were defined
as intervals between HypoCCS entry and the event dates.
For the remainder of the patients, person-years were
defined as intervals between the HypoCCS entry and the
last visit date recorded in the database.
To compare the observed results in HypoCCS and the
general population, standardized mortality ratios (SMRs)
and standardized incidence ratios (SIRs) for de novo cancer
in patients without a prior reported cancer were estimated by
computing a ratio between the number of events observed
and that expected. The expected incidence was determined
using gender- and age-specific incidence rates for the general
population in the United States and other countries partici-
pating in HypoCCS. Observed and expected counts for each
country were obtained by sum of the gender- and age-specific
strata for that respective country. An estimate of the overall
SIR or SMR was calculated using pooled results from all
countries that participated in HypoCCS, including those with
no AEs reported. 95 % confidence intervals (CIs) for the
results from the data following a Poisson distribution are
presented in all instances [12]. US reference mortality rates
were obtained from the Centers for Disease Control and
Prevention [13], and non-US reference mortality rates from
the World Health Organization [14]. US reference cancer
incidence rates were derived from SEER [15], and others
from GLOBOCAN [16]. The country-specific SMR or SIR
was also reported. Because for every additional country
analysis, there is an increased chance of type I error (error of
falsely rejecting null hypothesis that there is no increased
risk) [17], an observed significant result may be prone to be a
false discovery. However, for purpose of safety surveillance,
this type I error was not adjusted. Thus, without this
adjustment, we used stringently conservative methods in
reporting the comparison between the HypoCCS and each of
its reference populations.
Because population-based reference data for MI and
stroke were not readily available for estimating SIRs, only
crude incidence rates were computed for MI and stroke for
HypoCCS patients and are presented along with published
reports [18, 19].
Results
Characteristics of COGHD and ICOGHD groups
One thousand two hundred and four childhood-onset GHD
patients were identified in the COGHD group who had
been treated with GH during childhood and had available
information on age, gender, and follow-up (Table 1). This
group had a mean age of 26.8 years, 37 % were female,
and mean follow up was 3.7 years. The mean GH dose
reported in HypoCCS was 540 lg/day. The reported
starting age for GH administration in childhood was
11.3 years. The mean durations of GH therapy before the
age of 18 years, the age of 21 years, and HypoCCS entry
were 6.6, 7.1, and 7.5 years, respectively. Of this group,
1,086 patients (90.2 % of 1,204) received GH therapy as
adults. Causes of GH deficiency included history of cra-
niopharyngioma (20.9 %), history of other intracranial
tumors (15.3 %), congenital defects (8.9 %), empty sella





Age (years) at HypoCCS entry,
mean (SD)
26.8 (8.6) 27.6 (8.8)
Gender (female), n (%) 449 (37.3) 131 (33.7)
Total follow-up (years)
in HypoCCS mean (SD)
3.7 (3.3) 4.2 (3.6)
Mean GH dose (lg/day) for GH
treated in HypoCCS, mean (SD)
539.4 (333.2) 538.9 (298.9)
Reported age of starting
GH therapy, mean (SD)
11.3 (7.2) 10.0 (6.1)
GH therapy duration before age
18 years, mean (SD)
6.6 (4.2) 7.2 (4.0)
GH therapy duration before age
21 years, mean (SD)
7.1 (4.5) 7.7 (4.4)
GH therapy duration prior to
HypoCCS entry, mean (SD)
7.5 (4.3) 8.0 (5.1)
Causes of GHD, n (%)
Idiopathic GHD 389 (32.3) 389 (100.0)
Craniopharyngioma 252 (20.9)
Intracranial tumor (other than
craniopharyngioma)
184 (15.3)
Congenital defect, type unknown 107 (8.9)
Empty sella 71 (5.9)
Pituitary hemorrhage or infarct 30 (2.5)
Known genetic defect 23 (1.9)




Intracranial tumor (other than craniopharyngioma) includes germi-
noma, dysgerminoma, pituitary adenoma, medulloblastoma, astrocy-
toma glioma and meningioma, Rathke’s cleft cyst, and histiocytosis.
Others includes pituitary abscess or other infection, head injury, and
other causes
GH growth hormone, GHD growth hormone deficiency, COGHD
group those patients with childhood-onset GH deficiency who
received GH replacement during childhood and had available infor-
mation on age, gender, and at least one follow-up visit, HypoCCS
Hypopituitary Control and Complications Study, ICOGHD group an
idiopathic subgroup of the COGHD patients, SD standard deviation
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(5.9 %), and idiopathic (32.3 %). About 30 % of patients
were from the United States, 15 % from Italy, 9 % from
Germany, 9 % from Spain and 8 % from Japan and the
remaining 29 % from Canada and 11 European countries.
In the ICOGHD group, 389 patients were identified who
had a longer mean follow-up duration (4.2 years for
ICOGHD vs. 3.7 for COGHD) and an earlier starting age of
GH therapy (10 years vs. 11.3).
Mortality
Ten deaths were reported in the COGHD group. The
majority of deaths occurred in males (n = 8). All deaths
occurred at relatively young ages (n = 5 in the age group
20–29 years, n = 4 in 30–39, and n = 1 in 40–49).
Patients died from a variety of causes [3 from infections, 2
from tumors (1 glioblastoma and 1 craniopharyngioma
recurrence or meningioma), 2 from suicide, 1 from grand
mal seizure, 1 from stroke, and 1 from Creutzfeldt-Jakob
disease]. No patient died from MI or cardiac disorders
(cardiomyopathy and cardiomegaly). One death was iden-
tified in the ICOGHD group and assumed to be at no
increased risk. This patient was a male aged 20–29 years
who died from Creutzfeldt-Jakob disease. He had previ-
ously received human pituitary extracted GH rather than
recombinant GH during ages 2–9 years for childhood-onset
idiopathic GH deficiency. He had received GH only as a
child, never as an adult, but was enrolled in HypoCCS. The
investigator reported that the event was related to the
childhood exposure to human-derived GH but not to study
procedures or adult treatment with GH. Comprehensive
review of the other 9 deaths from the COGHD group
showed that all had complex underlying conditions,
including intracranial tumor and/or surgery, radiotherapy,
and hypopituitarism, and thus had increased risk of pre-
mature death [6, 19, 20].
Crude mortality rates and SMRs were calculated for each
country and for all countries combined to quantitatively
evaluate overall mortality rates in the COGHD group
(Table 2). A non-statistically significant SMR (1.14, 95 %
CI 0.55–2.10) was observed for the relative risk of the
mortality after adjusting for age, gender, and country,
suggesting no difference in mortality relative to the general
population for this group of patients. Country-specific
SMRs (or differences from respective general populations)
were not statistically significant for any of the countries
except for the United Kingdom. The significant UK SMR
(10.81, 95 % CI 2.23–31.58) resulted from the reported 3
deaths. All 3 cases had complex underlying medical con-
ditions and were subject to increased risk of premature
death. The first patient was a male aged 40–49 years whose
death was reported as ‘‘possible suicide’’ from carbon
monoxide and alcohol poisoning. The investigator reported
the death as unrelated to study drug or protocol procedure.
This case was complex; the patient had childhood-onset GH
deficiency with a diagnosis of empty pituitary sella and
panhypopituitarism, and he had a history of vertebral disk
protrusion and prior surgical removal of malignant mela-
noma. His concomitant medications included thyroxine for
hypothyroidism, hydrocortisone for hypoadrenalism, tes-
tosterone for hypogonadism, diclofenac for vertebral disc









SMR (95 % CI)
Czech Republic 27 141.4 707.2 (17.9–3,940.4) 1 0.299 3.35 (0.08–18.64)
France 125 372.2 806.0 (166.2–2,355.6) 3 0.927 3.24 (0.67–9.46)
Germany 113 505.22 197.9 (5.0–1,102.8) 1 1.12 0.89 (0.02–4.97)
Netherlands 66 474.74 210.6 (5.3–1,173.6) 1 0.779 1.28 (0.03–7.15)
United Kingdom 40 160.81 1,865.5 (384.7–5,451.9) 3 0.278 10.81 (2.23–31.58)
United States 359 1,134.8 88.1 (2.2–491.0) 1 1.931 0.52 (0.01–2.89)
Overall 1,204 4,462.4 224.0 (107.5–412.1) 10 8.751 1.14 (0.55–2.10)
Mortality rate per 100,000 person-years = observed number of deaths 9 100,000/total person-years. Expected number of deaths = sum of
person-years 9 incidence rate for each age-gender group. Overall expected number of deaths = sum of expected deaths in each country. Overall
observed number of deaths = sum of observed deaths in each country. Data for those countries without a death event are not depicted. However,
the total person-years of follow-up and expected number of deaths are included in the overall estimate row. SMR = observed number of deaths/
expected number of deaths. 95 % CI is the exact confidence interval based on Poisson distribution. Reference data sources for calculating
expected cases: http://wonder.cdc.gov/ for US data and http://apps.who.int/ghodata/ for non-US data
CI confidence interval, COGHD group those patients with childhood-onset GH deficiency who received GH replacement during childhood and
had available information on age, gender, and at least one follow-up visit, GH growth hormone, N number of patients, SMR standardized
mortality ratio
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protrusion, alendronate sodium for osteoporosis, and para-
cetamol/codeine for back pain. The dose of GH adminis-
tered at HypoCCS enrollment was 600 lg/day. The other
two cases were males with history of surgery and/or
radiotherapy and of hypopituitarism. One was aged
30–39 years and died from bronchopneumonia and
encephalopathy, and the other, aged 20–29 years, died from
acute fulminant pancreatitis with known risk factors
[obesity (BMI 35 kg/m2) and hypertriglyceridemia] for
pancreatitis. In both cases, the investigators listed the
findings as unrelated to GH treatment or study protocol.
A non-statistically significant SMR [0.33 (95 % CI
0.01–1.84)] was observed for the ICOGHD group (Idio-
pathic COGHD who had received prior pediatric GH
treatment), suggesting no increased mortality risk in this
group.
Cancer
In COGHD group, one incident case of cancer was iden-
tified in those patients without a prior cancer (n = 1,056)
(Table 3), and the case was reported in the mortality ana-
lysis. This was a male patient diagnosed with malignant
melanoma which was surgically removed on the left upper
arm at the age 41. The patient had a history of childhood-
onset GH deficiency associated with empty pituitary sella
(the concomitant medications of thyroxine, hydrocortisone,
testosterone, diclofenac, alendronate sodium, and paracet-
amol/codeine were listed in the part of mortality results).
One year after surgical tumor resection, the patient com-
mitted suicide (see previous description in the mortality
results). A non-statistically significant SIR (0.27, 95 % CI
0.01–1.50) was observed for the relative risk of the overall
incidence of cancer by adjusting for age, gender, and
country. No new cancer case occurred in the ICOGHD
group.
Myocardial infarction
No incident case of MI was identified in either the COGHD
or the ICOGHD group.
Stroke
In the COGHD group, 8 incident stroke cases (1 hemor-
rhage, 5 ischemia, and 2 unspecific) were identified. The
only incident hemorrhagic stroke (cerebral hemorrhage)
occurred in a male patient aged 20–29 with an astrocytoma
diagnosed at the age of 2 years and a history of pituitary
surgery, radiotherapy, and panhypopituitarism. The 5
incident cases of ischemic stroke (2 cerebral infarctions,
2 lacunar infarctions, and 1 Moyamoya disease) in this
group had undergone brain surgery and radiotherapy for
brain tumors (4 craniopharyngioma cases and 1 astrocy-
toma), and also recorded other risks including panhypopi-
tuitarism, obesity, and metabolic syndrome. Two incident
cases diagnosed as stroke and apoplexy were not specified
as hemorrhagic or ischemic. One was reported to be sec-
ondary to meningocele surgery, and the other had a history
of brain surgery and radiotherapy for craniopharyngioma.
None of these strokes was considered related to the GH
therapy by the reporting investigators. No stroke was
identified in the ICOGHD group.
For the COGHD group, crude incidence rates for hem-
orrhagic stroke and ischemic stroke were calculated
(Table 4) in each participating country and in all countries.
The 8 cases resulted in a crude incidence rate of 181.28
(95 % CI 78.26–357.19) per 100,000 person-years.
Discussion
This HypoCCS analysis focused on adult patients who had
received prior GH treatment for COGHD during









SMR (95 % CI)
United Kingdom 31 127.2 786.3 (19.9–4,381.0) 1 0.119 8.37 (0.21–46.6)
Overall 1,056 3,965.4 25.2 (0.6–140.5) 1 3.718 0.27 (0.01–1.50)
Incidence rate per 100,000 person-years = observed number of incident events 9 100,000/total person-years. Expected number of
events = sum of person-years 9 incidence rate for each age-gender group. Overall expected number of events = sum of expected incident
events in each country. Overall observed number of events = sum of observed incident events in each country. Data for those countries without
an event are depicted. However, the total person-years of follow-up and expected number of deaths are included in the overall estimate row.
SIR = observed number of events/expected number of events. 95 % CI is the exact confidence interval based on Poisson distribution. Reference
data sources for calculating expected cases: http://seer.cancer.gov/statistics for US data and http://globocan.iarc.fr for non-US data
CI confidence interval, COGHD group those patients with childhood-onset GH deficiency who received GH replacement during childhood and
had available information on age, gender, and at least one follow-up visit, GH growth hormone, N number of patients, SIR standardized incidence
ratio
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childhood. This allowed for observation of potential
increased clinical risk (mortality, cancer, stroke, and MI)
during adulthood in COGHD patients who were formerly
pediatric patients. No increased mortality was observed in
the COGHD group compared with the general population
(as measured by an SMR of 1.14, 95 % CI 0.55–2.10)
after adjusting for age, gender, and country. Furthermore,
increased country-specific mortality was not observed in
any of the 17 participating countries except the UK.
It is difficult to attribute this observed increased UK
mortality to GH therapy because all three cases had com-
plex underlying conditions and were vulnerable to
increased risk of premature death. Additionally, the sta-
tistical significance for the higher mortality in the UK
could also be a false positive, as a type I error was not
adjusted for in the multiple comparisons in 17 countries
[17]. For every additional country analyzed, there was an
increased chance of type I error due to multiplicity. The
further subgroup analysis for the ICOGHD group allowed
for observation of a group assumed to be at no increased
risk. The only death in the ICOGHD group was due to
Creutzfeldt-Jakob disease related to prior use of human
cadaveric derived GH product [21]. Furthermore, the
observation of no mortality increase for ICOGHD patients
in HypoCCS is consistent with the observations in the
SAGhE cohorts from Sweden, Belgium, and the Nether-
lands [2] and that in idiopathic GHD patients from a
Danish cohort [22]. Therefore, the result of the mortality
analysis does not indicate that recombinant GH during
childhood is related to increased mortality in either the
COGHD or ICOGHD groups.
There was only one incident cancer case (malignant
melanoma) identified in the COGHD group. This case led
to a non-significant SIR (0.27, 95 % CI 0.01–1.50). Even
with the point estimate close to 0.3, the wide confidence
interval made it difficult to draw conclusions of a lower
risk of cancer occurrence compared with the general pop-
ulation. It is reassuring that we observed no occurrence of
new cancers in the ICOGHD group (the low-risk group). In
contrast with the French SAGhE data [1], no incident case
of malignant neoplasm of the bone or articular cartilage
was observed in the COGHD or ICOGHD subjects in
HypoCCS [1]. No case of MI was identified in either the
COGHD or ICOGHD groups.
Because appropriate reference data are not available in
the literature, it is not possible to calculate stroke SIR in
which age, gender, and country factors can be adjusted for
when comparing the HypoCCS COGHD group and refer-
ence populations. Overall stroke incidences in the general
population were reported in the United States, European
countries (France, Italy, Lithuania, Spain, Poland, and the
United Kingdom), and Japan. They ranged from 101 (male)
and 63 (female) per 100,000 person-years in Italy and 189
in the United States, to 239 (male) and 159 (female) in
Lithuania [18, 19, 23]. In contrast, the stroke rate in
HypoCCS COGHD group was 181.28 (95 % CI
78.26–357.19) per 100,000 person-years. Although the
point estimate of stroke incidence in HypoCCS COGHD
group appeared to be at the high end of the risk range
reported in the literature, it is not possible to draw con-
clusions favoring increased stroke risk due to the wide
confidence intervals resulting from a small sample size, and
Table 4 Crude incidence of stroke by country for COGHD group
Country N Follow-up years Stroke type Number of cases Crude incidence rate (per 100,000
person-years) (95 % CI)
France 121 361.3 Unspecific 1 276.8 (7.0–1,542.0)
Germany 112 502.1 Unspecific 1 199.25 (5.0–1,109.6)
Japan 90 136.6 Ischemia 1 732.2 (18.5–4,079.8)
United Kingdom 40 160.8 Ischemia 1 621.9 (15.7–3,464.7)
United States 356 1,130.9 Hemorrhage 1 88.4 (2.2–492.7)
Ischemia 3 265.3 (54.7–775.3)
Overall 1,189 4,413.1 Hemorrhage 1 22.7 (0.6–126.3)
Ischemia 5 113.3 (36.8–264.4)
Unspecific 2 45.3 (5.5–163.7)
Overall 8 181.3 (78.3–357.2)
Two cases of subarachnoid hemorrhage due to trauma were excluded from the crude incidence rate estimate according to the stroke study in
Minnesota stroke registry methodology (11). Incidence rate per 100,000 person-years = observed number of incident events 9 100,000/total
person-years. Data for those countries without an event are not depicted. However, the total person-years of follow-up are included in the overall
estimate row. 95 % CI is the exact confidence interval based on Poisson distribution
CI confidence interval, COGHD group those patients with childhood-onset GH deficiency who received GH-replacement during childhood and
had available information on age, gender, and at least one follow-up visit, GH growth hormone, N number of patients
482 Pituitary (2014) 17:477–485
123
also due to age and gender which could not be adjusted in
this analysis. Importantly, all stroke patients in the COGHD
group had at least one of the following risk factors: brain
surgery and/or radiotherapy due to brain tumor, panhypo-
pituitarism, obesity and other metabolic risks. Adult GH
deficient patients, especially patients harboring organic
brain lesions, were at higher risk of cerebrovascular dis-
eases [7, 20, 24] Adult GH deficient patients were reported
to exhibit high prevalence of metabolic syndrome, which
predisposed them to a high risk of cerebrovascular diseases
[9, 10, 25]. In fact, GH deficiency itself is a risk factor: low
levels of IGF-I resulting from GH deficiency may also
contribute to atherosclerosis and cerebrovascular disease
[24]. Nevertheless, even with a relatively small sample
size, it is reassuring that we observed no occurrence of
stroke among ICOGHD group, since these patients are free
from organic brain lesions and with no increased risk of
cerebrovascular disease at baseline. Thus, our results do
not provide evidence supporting increased risk of stroke in
the COGHD patients or ICOGHD group who had previ-
ously received pediatric GH treatment.
Although statistical analyses and comprehensive case
review do not support evidence for increased risk of mor-
tality, stroke, cancer, and MI in the COGHD patients, the
following limitations of this analysis are acknowledged.
First, the analyses were impeded by the relatively short
observation duration (a mean 3.7 years of adulthood fol-
low-up) and the small sample size (n = 1,204) of the
COGHD group (Table 1). The sample size for this
HypoCCS analysis is approximately 20 % of the French
SAGhE cohort. Second, it is not directly comparable
between the French SAGhE cohort and the HypoCCS
cohort. The majority of French SAGhE patients (approxi-
mate 75 %) were idiopathic isolated GHD (no multiple
pituitary hormone deficiencies) [1]. The similar group in
HypoCCS was the ICOGHD group which included both
isolated GHD and multiple pituitary hormone deficiencies
of unknown etiology. Given this difference in etiology of
GH deficiency, it is plausible that the HypoCCS ICOGHD
group actually reflects a higher risk group. Nevertheless,
we found no safety signal. The third limitation is a possible
selection bias as the COGHD group comprised those with
persistent childhood-onset GH deficient patients [26].
Patients in HypoCCS with COGHD must have been diag-
nosed by their adult endocrinologist with persistent GH
deficiency and chosen to be enrolled into HypoCCS.
Childhood-onset GH deficient patients who had known
active malignant tumors were excluded from HypoCCS
according to the protocol. Accordingly, results of this
analysis cannot be extrapolated to all childhood-onset GH
deficient patients. However, this analysis enabled unique
observation of potential increased risk of mortality/mor-
bidity during adulthood in COGHD patients who were
formerly treated with GH as pediatric patients, and who
demonstrated persistent GH deficiency during adulthood,
and were in need of continued GH replacement therapy
during the transition period and adulthood [27]. While the
French SAGhE cohort stopped GH therapy at a mean age
of 15.1 years [1], 90.2 % of the HypoCCS cohort received
GH therapy as adults. Mean duration of GH therapy was
3.9 years in the French SAGhE [1], but longer durations of
GH therapy (6.6 years before the age of 18, 7.1 years
before the age of 21, and 7.5 years before HypoCCS entry)
were reported in the HypoCCS cohort. Because of persis-
tent GH deficiency and entirely different background dis-
ease entities (except for ICOGHD) in HypoCCS, the
HypoCCS cohort serves as an important complementary
cohort for observations that could not be included in the
SAGhE study. Importantly, the reported duration of GH
therapy prior to HypoCCS had been accumulated mostly
before the age of 18 years (i.e., 6.6 years out of 7.5 years),
and only approximately 1 further year of GH therapy was
reported during a period of 9 years following the age of
18 years to HypoCCS entry (with a mean age of 26.8 years
at entry; Table 1). The HypoCCS data indicate that many
patients who had received prior GH therapy during child-
hood did not transition to GH therapy during adulthood
beyond the cessation of linear growth. In practice, many
patients with childhood onset GH deficiency are not
retested for GH deficiency during this transition [27].
These HypoCCS results suggest the need for future edu-
cation discussion regarding transition therapy. Fourthly,
detailed GH dosing information (lg/kg/day) during child-
hood was not available in HypoCCS for COGHD patients
because it was not specified in the study protocol.
Approximately 16 years elapsed between the time patients
initiated pediatric GH therapy and the time of HypoCCS
enrollment (i.e., from starting GH treatment at age
11.3 years to HypoCCS entry at age 26.8 years; Table 1).
However, important information on history of AEs (e.g.,
types of brain tumor) and risk factors (e.g., brain surgery,
radiotherapy, and chemotherapy) prior to HypoCCS
enrollment was collected, and these factors likely accoun-
ted for the occurrence of the observed AEs. Finally, the
small number of patients without GH replacement in
childhood (n = 65) restricted comparison between GH
treated and untreated pediatric patients. The size of the
idiopathic childhood onset subgroup of these 65 patients
was even smaller (n = 7). Despite the caveats discussed
above, this analysis of the HypoCCS database provides an
important opportunity to reassess mortality and morbidity
of cancer, MI, and stroke in adult GHD patients who had
previously received pediatric GH treatment.
In conclusion, the French SAGhE study [1] raised the
important question of increased adult mortality after prior
GH treatment in childhood. However, results of this
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surveillance study indicate no increased risk of mortality or
incidence of cancer, stroke, or MI in adult GH-deficient
patients who had received prior pediatric GH treatment.
Importantly, interpretation of the analysis is limited by the
selected patient population, a relatively short follow-up
duration, and lack of information on pediatric GH doses
administered.
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